Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL28934087 | 0.86 | PTGS2 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL27899616 | 0.76 | MEN1 (0.39) | HCRTR1HCRTR2BRD9MEN1KMT2A | |
| SCHEMBL22323697 | 0.75 | ALDH1A1 (0.50) | HCRTR1HCRTR2MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5384716 | 0.73 | ALDH1A1 (0.47) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1855131 | 0.73 | MEN1 (0.53) | HCRTR1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL22323949 | 0.72 | ENPP2 (0.43) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL29447077 | 0.72 | ENPP2 (0.43) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL10511000 | 0.72 | SIRT6 (0.45) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7134410 | 0.72 | MEN1 (0.52) | HCRTR1MEN1KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8498491 | 0.72 | CA1 (0.54) | MEN1KMT2ACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HCRTR1 4453/4885HCRTR2 4584/4885G6PD 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.